Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 553-557

  Sugioka, Koji ^a   Fukuda, Masahiko ^a   Komoto, Shohei ^a   Itahashi, Motoki ^a   Yamada, Masakazu ^b   Shimomura, Yoshikazu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Fluoroquinolone; Gatifloxacin; Levofloxacin; Moxifloxacin; Penetration; Rabbit

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; UNCLASSIFIED DRUG; VEGAMOX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DRUG PENETRATION; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; RABBIT;

EID: 77953368782     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s7757     Document Type: Article

References (11)

1. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133(4):463-466.
2. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136(3):500-505.
3. Diamond JP, White L, Leeming JP, Bing Hoh H, Easty DL. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthalmol. 1995;79(6):606-609.
4. Yamada M, Mochizuki H, Yamada K, Kawai M, Mashima Y. Aqueous humor levels of topically applied levofloxacin, norfloxacin, and lomefloxacin in the same human eyes. J Cataract Refract Surg. 2003;29(9):1771-1775.
5. Yamada M, Ishikawa K, Mochizuki H, Kawai M. Corneal penetration of simultaneously applied topical levofloxacin, norfloxacin and lomefloxacin in human eyes. Acta Ophthalmol Scand. 2006;84(2):192-196.
6. Yagci R, Oflu Y, Dincel A, et al. Penetration of second, third, and fourth generation topical flouroquinolone into aqueous and vitreous humor in a rabbit endophlamitis model. Eye. 2007;21(7):990-994.
7. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50(Suppl 1):S32-S45.
8. Fukuda M, Sasaki K. In vitro topically applied fluoroquinolone penetration into the anterior chamber. Nippon Ganka Gappai Zasshi. 1995;99(5):532-536.
9. Fukuda M, Sasaki H. Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions. Curr Med Res Opin. 2008;24(12):3479-3486.
10. Fukuda M, Sasaki K. General purpose antimicrobial ophthalmic solutions evaluated using new pharmacokinetic parameter of maximum drug concentration in aqueous. Jpn J Ophthalmol. 2002;46(4):384-390.
11. Leibowitz HM, Kupferman A. Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis. Arch Ophthalmol. 1977;95(4):682-685.